Published in Heart Disease Weekly, October 22nd, 2006
According to that review, "Levosimendan is a new calcium sensitizer and KATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischaemic effect."
L. Deluca and colleagues at European Hospital in Rome wrote, "The documentation regarding levosimendan is one of the largest ever on the safety and efficacy of a new pharmacological agent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.